Impaired Glucose Tolerance Clinical Trial
Official title:
AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus
The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease. Teplizumab has been studied in new onset type 1 diabetes for testing of efficacy and safety in previous studies; other studies are currently in progress. The results of previous studies indicate that teplizumab reduces the loss of insulin production during the first year after diagnosis in individuals with type 1 diabetes. The purpose of this study is to determine if teplizumab can interdict the immune process that causes the destruction of insulin secreting beta cells in the pancreas during the "pre-diabetic" state and thereby prevent or delay the onset of type 1 diabetes.
The study plans to enroll approximately 71 subjects between the ages of 8-45 years, over 2-3
years. The study is projected to last between 4-6 years, depending upon rate of enrollment
and number of subjects who develop diabetes.
The main study objective is to determine whether intervention with teplizumab will prevent or
delay the development of type 1 diabetes in high risk autoantibody positive non-diabetic
relatives of individuals with T1D. Secondary outcomes are to include analyses of C-peptide
and other measures from Oral Glucose Tolerance Testing (OGTT), safety, tolerability, and
other mechanistic outcomes will be assessed during the study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05354245 -
Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)
|
N/A | |
Completed |
NCT04088461 -
Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine
|
Phase 4 | |
Completed |
NCT02621060 -
Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance
|
Phase 2 | |
Completed |
NCT01521312 -
ACute and Chronic Effects of Saxagliptin
|
Phase 2 | |
Completed |
NCT01488279 -
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
|
N/A | |
Completed |
NCT01559896 -
Egg Protein Hydrolysate and Vascular Function
|
N/A | |
Completed |
NCT01030978 -
Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program
|
N/A | |
Completed |
NCT00573781 -
Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism
|
Phase 2 | |
Terminated |
NCT00846521 -
Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity
|
Phase 4 | |
Completed |
NCT00241072 -
Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance
|
Phase 4 | |
Completed |
NCT00536250 -
Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth
|
N/A | |
Completed |
NCT02254317 -
Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance
|
N/A | |
Completed |
NCT03764423 -
Health Effects of Salmon Fishmeal in Humans
|
N/A | |
Recruiting |
NCT05347030 -
Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population
|
N/A | |
Active, not recruiting |
NCT04341571 -
Effect of Probiotics Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes.
|
Phase 2 | |
Completed |
NCT02700334 -
Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes
|
Phase 4 | |
Active, not recruiting |
NCT01933529 -
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
|
Phase 2 | |
Completed |
NCT02135172 -
Breaks in Sedentary Time and Glucose Regulation in Women
|
N/A | |
Active, not recruiting |
NCT01841229 -
Effect of Ginseng on Glycemic Control
|
N/A | |
Completed |
NCT02248272 -
Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes
|
N/A |